Publisher
Springer Berlin Heidelberg
Reference40 articles.
1. DiMagno EP, Reber HA, Tempero MA (1999) American Gastroenterological Association Médical Position Statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117;1463–1484
2. Lowenfels AB, Maisonneuve P, Cavallini G et al (1993) Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328; 1433–1437
3. Ghane P, Katscha A, Evans JD, Neoptolemos P, Molecular prognositic markers in pancreatic cancer. (2002) J Hepatobiliary Pancreat Surg 9; 1–11
4. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger H (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin Invest 90; 1352–1360
5. Gansauge F, Gansauge S, Schmidt E, Müller J, Beger HG (1998) Prognostic significance of molecular alterations in human pancreatic carcinoma — an immunohistological study. Langenbeck’s Arch Surg 383; 152–155